EU | Jotup

Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates

Retrieved on:

Mercredi, novembre 8, 2023

Based on the current operating plan, the Company is on-track to achieve non-GAAP profitability2 in the fourth quarter of 2023, a major milestone for Amicus.

Key Points:

Based on the current operating plan, the Company is on-track to achieve non-GAAP profitability2 in the fourth quarter of 2023, a major milestone for Amicus.
Total revenue in the third quarter 2023 was $103.5 million, a year-over-year increase of 27% from total revenue of $81.7 million in the third quarter 2022.
ET to discuss the third quarter 2023 financial results and corporate updates.
A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com .

Transaction in Own Shares

Retrieved on:

Mercredi, novembre 8, 2023

Listing Rules, Financial Services Act, Market abuse, Shell, Financial Services Act 2012, Goldman Sachs, European Union (Withdrawal Agreement) Act 2020, European Union (Withdrawal) Act 2018, Withdrawal, European, Brexit, EU

These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 2 November 2023.

Key Points:

These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 2 November 2023.
In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 2 November 2023 up to and including 26 January 2024.
The on-market limb will be effected within certain pre-set parameters and in accordance with the Company's general authority to repurchase shares on-market.
The off-market limb will be effected in accordance with the Company's general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein.

Norsk Hydro: Status share buyback program

Retrieved on:

Mercredi, novembre 8, 2023

Security (finance), Disclosure, ASA, EU, Share repurchase, Norsk Hydro

Prior to the share buyback program Norsk Hydro ASA owned a total of 15 096 878 own shares.

Key Points:

Prior to the share buyback program Norsk Hydro ASA owned a total of 15 096 878 own shares.
Following the above listed transactions, Norsk Hydro ASA owns a total of 22 838 744 shares, corresponding to 1.12% of Norsk Hydro ASA's share capital.
Attachment: An overview of all the completed transactions under the program for the dates specified above is attached to this notification and available on www.newsweb.no.
This is information that Norsk Hydro ASA is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Botanical Solution Inc. (BSI) Wins 2023 Best Product/Service of the Year Award at UK’s Big Sustainability Award Competition

Retrieved on:

Mercredi, novembre 8, 2023

Botanical Solution Inc. (BSI) has been named winner of the 2023 Sustainable Product/Service of the Year Award from the UK’s Big Sustainability Awards.

Key Points:

Botanical Solution Inc. (BSI) has been named winner of the 2023 Sustainable Product/Service of the Year Award from the UK’s Big Sustainability Awards.
View the full release here: https://www.businesswire.com/news/home/20231108489060/en/
Botanical Solution Inc. (BSI) wins the UK's Big Sustainability Award for Best Product or Service of the Year.
Croda Pharma announced the partnership with BSI earlier this year and launched this award-winning innovation subsequently to their global customer base.
Botanical Solution’s winning of the Big Sustainability Award for Best Product/Service of the Year is the 4th industry award BSI has received in the past year, having also won the ICIS Chemical Business Process Innovation Award, the Best Biopesticide of the Year from S&P CropScience, and the Best Startup Business of the Year Award from the World BioProtection Forum.

CommunityWFM Completes GDPR Audit and Receives SOC 2 Type II Certification

Retrieved on:

Mercredi, novembre 8, 2023

Software, Technology, Carriers and Services, Security, SOC, AICPA, Certification, General Data Protection Regulation, Privacy, Confidentiality, European, SOC 2, GDPR, Audit, Medical device, EU

CommunityWFM, one of the premier contact center workforce management software solutions in the industry, today announced that it has completed its GDPR and SOC 2 Type II audit, performed by KirkpatrickPrice , and received an attestation from the security firm.

Key Points:

CommunityWFM, one of the premier contact center workforce management software solutions in the industry, today announced that it has completed its GDPR and SOC 2 Type II audit, performed by KirkpatrickPrice , and received an attestation from the security firm.
A SOC 2 audit provides an independent, third-party validation that a service organization’s information security practices meet industry standards stipulated by the AICPA.
“The SOC 2 audit is based on the Trust Services Criteria,” said Joseph Kirkpatrick, President of KirkpatrickPrice.
“The CommunityWFM system was designed from the ground up to maximize data security,” said Peter Schmidt, CTO of CommunityWFM.

Ferguson Share Repurchase Program - Weekly Report

Retrieved on:

Mercredi, novembre 8, 2023

HVAC, Manufacturing, Treasury, Article, European Union (Withdrawal) Act 2018, Ferguson, Disclosure, Security (finance), EU

The Company intends to hold these shares in treasury.

Key Points:

The Company intends to hold these shares in treasury.
Following the purchase of these shares (including those purchased but not yet settled), the number of shares held by the Company in treasury will be 28,438,874.
Following the purchase of these shares, the remaining number of ordinary shares in issue will be 203,732,308.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018, and the Commission Delegated Regulation (EU) 2016/1052, detailed information about the individual purchases can be found at Ferguson - Investors - Shareholder Center - Share Buy-Back Details - 2023 Share Buy-Back .

European Employers Navigate New Pressures Around Flexible Work Models, AI Adoption and Divisive Social Issues, Littler Survey Finds

Retrieved on:

Mercredi, novembre 8, 2023

Littler, the world’s largest employment and labour law practice representing management, has released its sixth annual European Employer Survey Report .

Key Points:

Littler, the world’s largest employment and labour law practice representing management, has released its sixth annual European Employer Survey Report .
The breakdown between in-person and remote work in this year’s survey remains remarkably similar to Littler’s 2022 European Employer Survey .
European employers also seem to be placing higher value on in-office collaboration than their American counterparts, as Littler’s 2023 U.S.
Employer Survey found that only 16% require fully in-person work while 71% operate on a hybrid schedule.

Indemo Revolutionizes Debt Investments

Retrieved on:

Mercredi, novembre 8, 2023

Professional Services, Socially Responsible Investing, Finance, Asset Management, Banking, Accounting, Sale, Policy, Eurozone, Democracy, Investment, DDI, Bank, Credit, Life insurance, EU

Indemo , Europe's pioneering MIFID-licensed debt investing platform, is proud to announce its groundbreaking launch.

Key Points:

Indemo , Europe's pioneering MIFID-licensed debt investing platform, is proud to announce its groundbreaking launch.
This innovative platform empowers retail investors by granting access to Discounted Debt Investments, a privilege once reserved for bankers and institutional investors.
At Indemo, which means Investment Democracy, we prioritize transparency and adhere to stringent regulations, providing a trusted space for investment."
The Indemo team doesn't develop the platform in isolation; they place immense value on the insights derived from community-based feedback.

3E in the Process of Acquiring French Workplace Safety Platform, Quick-FDS

Retrieved on:

Mercredi, novembre 8, 2023

Headquartered in Saint-Denis, France, Quick-FDS works with global manufacturers and users of chemical products, offering a full suite of solutions that enable improved regulatory compliance and workplace safety.

Key Points:

Headquartered in Saint-Denis, France, Quick-FDS works with global manufacturers and users of chemical products, offering a full suite of solutions that enable improved regulatory compliance and workplace safety.
Quick-FDS’ market-leading solution enables superior regulatory compliance and efficiency, allowing customers to focus on their business instead of navigating ever-changing regulations.
Robin Dualé, President of WEKA in France, said “The combination of 3E and Quick-FDS would unite two of the most sophisticated SDS management solutions globally.
The transaction would be subject to customary conditions including the prior staff representatives’ consultation and regulatory approvals.

Clinical Trial Computerised Systems and Electronic Data - Lessons Learned Implementing the New EMA Guideline, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Mercredi, novembre 8, 2023

Knowledge, Project management, ICON, Biotechnology, Clinical trial, EMA, Guideline, Senior, Collection, European, Medical device, EU

TORONTO, Nov. 8, 2023 /PRNewswire-PRWeb/ -- The new framework of globally applicable standards for clinical trial data, effective from September 9, 2023.

Key Points:

Attendees will learn about the scope of impact on electronic data and computerized systems in clinical trials.
The featured speakers will discuss lessons learned, inspection readiness and more.
TORONTO, Nov. 8, 2023 /PRNewswire-PRWeb/ -- The new framework of globally applicable standards for clinical trial data, effective from September 9, 2023.
All companies now need to implement the EMA guideline on computerised systems and electronic data in clinical trials if the data will be used to support a marketing authorization in the European Union (EU).